Connect your AI

Scholar Rock SRRK Financing Cash Flow

Financing Cash Flow at other companies

BiogenBIIB

-$43.8M-90.4%

Edgewise Therapeutics, Inc.EWTX

$12.17M+448%

PTC TherapeuticsPTCT

$6.4M-32.0%

Dyne Therapeutics, Inc.DYN

$7.06M-95.0%

Catalyst PharmaceuticalCPRX

-$12.87M-521%

Cogent Biosciences, Inc.COGT

$52.54M+110%

Other financials

Income statement

Revenue-—

Operating income-$102.0M-32.3%

Net income-$105.5M-41.2%

EPS (diluted)-$0.83-23.9%

Balance sheet

Cash & equivalents$430.5M+212%

Total debt$205.7M+226%

Total equity$276.0M-11.6%

Total assets$535.3M+31.3%

Cash flow

Operating cash flow-$82.1M-4.4%

CapEx$68.0K-74.9%

Free cash flow-$82.2M-4.1%

Valuation

Market cap$5.67B+85.5%

Profitability

Operating margin-231.8%—

Net margin-236.9%—

FCF margin-309.1%—

Returns & leverage

Return on equity-138.9%+60.1pp

Debt / equity0.7×+0.5×

Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Scholar Rock's financing cash flow?: Scholar Rock (SRRK) reported financing cash flow of $193.79M in Q1 2026.
How has Scholar Rock's financing cash flow changed year-over-year?: Scholar Rock's financing cash flow increased by 4548.3% year-over-year, from $4.17M to $193.79M.
What is the long-term trend for Scholar Rock's financing cash flow?: Over 3 years (2021 to 2025), Scholar Rock's financing cash flow has grown at a 71.9% compound annual growth rate (CAGR), from $44.95M to $228.4M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.